© 2025 MergersCorp M&A International.
© 2025 MergersCorp M&A International is a global brand operating through a number of professional firms and constituent entities (“Members”) located throughout the world to provide Investment Banking, Corporate Finance, and Advisory Services and other client-related professional services. The Member Firms (“Members”) are constituted and regulated in accordance with relevant local regulatory and legal requirements. For more details on the nature of our affiliation, please visit our Disclaimer: https://mergerscorp.com/disclaimer. MergersCorp M&A International's franchising program is not offered to individuals or entities located in the United States.
The franchising program is offered by MergersUK Limited, a UK Company with its registered office at 71-75 Shelton Street, Covent Garden, London, WC2H 9JQ, United Kingdom.
MergersCorp M&A International provides strategic business advisory services, including preparing companies for growth and capital access. Through partnerships with licensed investment bankers, clients can access tailored capital-raising solutions.
U.S. Investment Banking Securities transactions are exclusively conducted by Spektrum Capital Advisors LLC, a Registered Representative of, and Securities Products offered through, BA Securities, LLC, a FINRA-registered broker-dealer. Check the background of investment professionals associated with this site on Broker Check.
This Licensed Pharmaceutical Wholesale Business is a pioneering organization in the pharmaceutical industry, committed to enhancing the quality of life through innovative healthcare solutions. Established with a vision to address unmet medical needs, the company exemplifies excellence in research and development, focusing on the creation of unique therapies that cater to rare and complex diseases.
A Swiss-registered pharmaceutical wholesaler holds a valuable Good Distribution Practice (GDP) authorization from Swissmedic. The company possesses comprehensive wholesale licensing for pharmaceutical products, enabling both national and international trade operations, including import, export, and raw materials wholesale activities. Operating with a small team from its Winterthur location, the business is structured to serve the global pharmaceutical market.
Strategic Value Proposition
The primary asset of the company is its GDP license, which acts as a significant barrier to entry in the pharmaceutical wholesale sector. Total investment to date amounts to CHF 230,566.18, covering complete operational setup and regulatory compliance. The business offers flexibility in acquisition structure, with options for a financed complete purchase.
Swiss Pharmaceutical Industry & Tax Advantages
Switzerland’s pharmaceutical sector is a premier global hub, home to industry leaders and renowned for its quality and regulatory excellence. A licensed operation benefits from this prestigious ecosystem, where pharmaceutical products command premium pricing and enjoy streamlined access to both EU and global markets. The Swiss regulatory framework, while stringent, offers significant advantages through mutual recognition agreements with major markets, facilitating international trade operations.
From a tax perspective, Switzerland provides compelling advantages for pharmaceutical operations. The country’s corporate tax rates are among Europe’s most competitive, typically ranging from 11.9% to 21.6%, depending on the canton. Switzerland’s patent box regime allows for preferential taxation of patent-related income, with up to 90% tax relief on qualifying income. Additionally, companies can benefit from R&D super-deductions and tax-efficient handling of intellectual property rights. The stability and transparency of the Swiss tax system, combined with an extensive network of double taxation treaties, create an optimal environment for international pharmaceutical trade and investment.
The GDP authorization’s scope covers comprehensive pharmaceutical wholesale operations, positioning the acquirer for immediate market entry into the regulated pharmaceutical distribution sector. While currently pre-revenue, the established regulatory framework and operational infrastructure provide a turnkey solution for entering the Swiss and international pharmaceutical wholesale market.
Registration Address: Winterthur, Swiss
Type of Entity: GmbH
Banking Relationship: Zürcher Kantonal Bank
Regulatory Licence: Swissmedic GDP
© 2025 MergersCorp M&A International is a global brand operating through a number of professional firms and constituent entities (“Members”) located throughout the world to provide Investment Banking, Corporate Finance, and Advisory Services and other client-related professional services. The Member Firms (“Members”) are constituted and regulated in accordance with relevant local regulatory and legal requirements. For more details on the nature of our affiliation, please visit our Disclaimer: https://mergerscorp.com/disclaimer. MergersCorp M&A International's franchising program is not offered to individuals or entities located in the United States.
The franchising program is offered by MergersUK Limited, a UK Company with its registered office at 71-75 Shelton Street, Covent Garden, London, WC2H 9JQ, United Kingdom.
MergersCorp M&A International provides strategic business advisory services, including preparing companies for growth and capital access. Through partnerships with licensed investment bankers, clients can access tailored capital-raising solutions.
U.S. Investment Banking Securities transactions are exclusively conducted by Spektrum Capital Advisors LLC, a Registered Representative of, and Securities Products offered through, BA Securities, LLC, a FINRA-registered broker-dealer. Check the background of investment professionals associated with this site on Broker Check.
This website is operated by MergersUS Inc a US Corporation with registered office at
Notifications
Description
This Licensed Pharmaceutical Wholesale Business is a pioneering organization in the pharmaceutical industry, committed to enhancing the quality of life through innovative healthcare solutions. Established with a vision to address unmet medical needs, the company exemplifies excellence in research and development, focusing on the creation of unique therapies that cater to rare and complex diseases.
A Swiss-registered pharmaceutical wholesaler holds a valuable Good Distribution Practice (GDP) authorization from Swissmedic. The company possesses comprehensive wholesale licensing for pharmaceutical products, enabling both national and international trade operations, including import, export, and raw materials wholesale activities. Operating with a small team from its Winterthur location, the business is structured to serve the global pharmaceutical market.
Strategic Value Proposition
The primary asset of the company is its GDP license, which acts as a significant barrier to entry in the pharmaceutical wholesale sector. Total investment to date amounts to CHF 230,566.18, covering complete operational setup and regulatory compliance. The business offers flexibility in acquisition structure, with options for a financed complete purchase.
Swiss Pharmaceutical Industry & Tax Advantages
Switzerland’s pharmaceutical sector is a premier global hub, home to industry leaders and renowned for its quality and regulatory excellence. A licensed operation benefits from this prestigious ecosystem, where pharmaceutical products command premium pricing and enjoy streamlined access to both EU and global markets. The Swiss regulatory framework, while stringent, offers significant advantages through mutual recognition agreements with major markets, facilitating international trade operations.
From a tax perspective, Switzerland provides compelling advantages for pharmaceutical operations. The country’s corporate tax rates are among Europe’s most competitive, typically ranging from 11.9% to 21.6%, depending on the canton. Switzerland’s patent box regime allows for preferential taxation of patent-related income, with up to 90% tax relief on qualifying income. Additionally, companies can benefit from R&D super-deductions and tax-efficient handling of intellectual property rights. The stability and transparency of the Swiss tax system, combined with an extensive network of double taxation treaties, create an optimal environment for international pharmaceutical trade and investment.
The GDP authorization’s scope covers comprehensive pharmaceutical wholesale operations, positioning the acquirer for immediate market entry into the regulated pharmaceutical distribution sector. While currently pre-revenue, the established regulatory framework and operational infrastructure provide a turnkey solution for entering the Swiss and international pharmaceutical wholesale market.
Keypoints
Registration Address: Winterthur, Swiss
Type of Entity: GmbH
Banking Relationship: Zürcher Kantonal Bank
Regulatory Licence: Swissmedic GDP
Basic Details
Target Price:
TBD
Gross Revenue
TBD
EBITDA
TBD
Business ID:
L#20250834
Country
Switzerland
City:
Winterthur
Detail
Similar Businesses
Published on February 7, 2025 at 9:24 pm. Updated on February 7, 2025 at 9:25 pm
40-Year-Old MENA Pharmaceutical Manufacturing Company
$45,000,000
Pharma
40 Year Old Pharmaceutical Manufacturing Business
$40,000,000
Manufacturing, Pharma
Historical Pharma Manufacturing Business
$1,050,000,000
Pharma
20-Year Old Pharmaceutical South American Brand
$11,500,000
Manufacturing, Pharma
Leading Research BioTech Company
TBA
Pharma
40 Year Old Rx-pharma Manufacturing Business
$12,000,000
Manufacturing, Pharma
PREVIOUS PROPERTY
Organic Food Producer and Exporter
NEXT PROPERTY
Mechanical Components Manufacturing Company